Free Trial

Accuray (ARAY) Competitors

$1.78
-0.03 (-1.66%)
(As of 06/7/2024 ET)

ARAY vs. UTMD, CTSO, SPNE, ANIK, SRDX, OFIX, ANGO, RMTI, RSLS, and ABT

Should you be buying Accuray stock or one of its competitors? The main competitors of Accuray include Utah Medical Products (UTMD), Cytosorbents (CTSO), SeaSpine (SPNE), Anika Therapeutics (ANIK), Surmodics (SRDX), Orthofix Medical (OFIX), AngioDynamics (ANGO), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), and Abbott Laboratories (ABT). These companies are all part of the "medical" sector.

Accuray vs.

Utah Medical Products (NASDAQ:UTMD) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

69.6% of Utah Medical Products shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 6.6% of Utah Medical Products shares are held by company insiders. Comparatively, 3.8% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Accuray has a consensus target price of $8.25, suggesting a potential upside of 363.48%. Given Utah Medical Products' higher possible upside, analysts clearly believe Accuray is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Utah Medical Products
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Accuray
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Utah Medical Products has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.

Utah Medical Products has a net margin of 33.40% compared to Utah Medical Products' net margin of -4.99%. Accuray's return on equity of 13.06% beat Utah Medical Products' return on equity.

Company Net Margins Return on Equity Return on Assets
Utah Medical Products33.40% 13.06% 12.30%
Accuray -4.99%-44.46%-4.54%

Accuray received 179 more outperform votes than Utah Medical Products when rated by MarketBeat users. Likewise, 65.67% of users gave Accuray an outperform vote while only 61.29% of users gave Utah Medical Products an outperform vote.

CompanyUnderperformOutperform
Utah Medical ProductsOutperform Votes
152
61.29%
Underperform Votes
96
38.71%
AccurayOutperform Votes
331
65.67%
Underperform Votes
173
34.33%

Utah Medical Products has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Utah Medical Products$49.04M4.85$16.64M$4.5014.98
Accuray$447.61M0.39-$9.28M-$0.22-8.09

In the previous week, Accuray had 3 more articles in the media than Utah Medical Products. MarketBeat recorded 3 mentions for Accuray and 0 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 0.47 beat Accuray's score of 0.00 indicating that Accuray is being referred to more favorably in the news media.

Company Overall Sentiment
Utah Medical Products Neutral
Accuray Neutral

Summary

Utah Medical Products beats Accuray on 9 of the 17 factors compared between the two stocks.

Get Accuray News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARAY vs. The Competition

MetricAccuraySurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$176.65M$3.92B$5.33B$8.17B
Dividend YieldN/A1.78%2.73%4.04%
P/E Ratio-8.0915.23167.3218.17
Price / Sales0.3964.142,423.0777.69
Price / CashN/A48.4535.2130.80
Price / Book3.184.314.974.33
Net Income-$9.28M$4.50M$110.34M$216.21M
7 Day Performance0.56%-1.09%-1.05%-1.43%
1 Month Performance6.59%-0.47%-0.61%-0.59%
1 Year Performance-51.63%-18.39%2.92%3.58%

Accuray Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTMD
Utah Medical Products
2.3298 of 5 stars
$67.33
-1.6%
N/A-32.4%$237.68M$50.22M14.96169Positive News
CTSO
Cytosorbents
0.9459 of 5 stars
$0.93
+4.5%
$2.00
+115.1%
-73.2%$50.51M$36.35M-1.58186Gap Down
SPNE
SeaSpine
0 of 5 stars
$9.54
flat
N/A+0.0%$354.92M$191.45M-5.39523Analyst Forecast
Gap Down
ANIK
Anika Therapeutics
2.5935 of 5 stars
$26.47
+0.3%
$30.50
+15.2%
-3.7%$391.31M$169.26M-5.04357
SRDX
Surmodics
3.1773 of 5 stars
$41.99
+0.0%
$50.00
+19.1%
+114.0%$598.78M$132.58M44.20376Analyst Forecast
High Trading Volume
OFIX
Orthofix Medical
1.0727 of 5 stars
$13.99
+1.5%
$18.00
+28.7%
-32.7%$525.05M$746.64M-4.141,634
ANGO
AngioDynamics
4.4001 of 5 stars
$6.50
+1.6%
$13.25
+103.8%
-37.4%$256.35M$324.01M-1.34815
RMTI
Rockwell Medical
3.9484 of 5 stars
$1.79
+1.7%
$7.00
+291.1%
-54.9%$54.27M$83.61M-4.97237
RSLS
ReShape Lifesciences
0 of 5 stars
$0.25
flat
N/A-90.7%$3.35M$8.68M0.0029Gap Down
ABT
Abbott Laboratories
4.9087 of 5 stars
$103.23
-0.2%
$120.64
+16.9%
+5.8%$179.58B$40.33B32.16114,000Analyst Forecast

Related Companies and Tools

This page (NASDAQ:ARAY) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners